Article
A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
3 Aug 2021
Abstract excerpt
We describe a Sanger sequencing protocol for SARS-CoV-2 S-gene the Spike (S)-glycoprotein product of which, composed of receptor-binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID-19. The protocol can be used in laboratories with basic Sanger sequencing capabilities and allows rapid "at source" screening for SARS-CoV-2 variants, notably those of concern. The protocol...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
